Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Consensus Price Target from Analysts

Key Points

• Zai Lab Limited (NASDAQ:ZLAB) has received an average rating of "Moderate Buy" from analysts, with one hold and six buy recommendations.
• The average price target for Zai Lab shares among analysts is $56.35, with notable ratings from firms like Leerink Partners and Citigroup.
• Insider trading activity includes CEO Ying Du selling 50,000 shares for approximately $1.74 million, indicating a decrease in insider ownership by 8.52%.

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $56.35.

ZLAB has been the subject of a number of research analyst reports. Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the company an "outperform" rating in a research note on Monday, June 30th. Wall Street Zen cut Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Jefferies Financial Group initiated coverage on Zai Lab in a research note on Monday, August 25th. They issued a "buy" rating and a $52.00 target price for the company. Finally, Citigroup reiterated a "buy" rating and set a $69.00 price target (up previously from $66.00) on shares of Zai Lab in a research report on Monday, August 11th.

Insider Activity at Zai Lab

In other news, insider Joshua L. Smiley acquired 10,000 shares of Zai Lab stock in a transaction on Wednesday, September 10th. The shares were purchased at an average price of $28.91 per share, with a total value of $289,100.00. Following the acquisition, the insider owned 86,604 shares in the company, valued at $2,503,721.64. This represents a 13.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ying Du sold 50,000 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $34.74, for a total value of $1,737,000.00. Following the completion of the transaction, the chief executive officer owned 536,962 shares in the company, valued at $18,654,059.88. The trade was a 8.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 215,710 shares of company stock valued at $7,589,684 over the last ninety days. Company insiders own 4.96% of the company's stock.

Hedge Funds Weigh In On Zai Lab

Several large investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its position in Zai Lab by 63.6% in the first quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock worth $104,257,000 after purchasing an additional 1,121,856 shares during the period. RTW Investments LP acquired a new stake in shares of Zai Lab during the 4th quarter worth approximately $65,714,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Zai Lab by 46,222.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock worth $77,058,000 after buying an additional 2,127,598 shares during the period. Allianz Asset Management GmbH raised its stake in shares of Zai Lab by 25.1% during the first quarter. Allianz Asset Management GmbH now owns 1,884,411 shares of the company's stock worth $68,103,000 after buying an additional 378,545 shares during the last quarter. Finally, Woodline Partners LP lifted its holdings in Zai Lab by 9.4% in the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company's stock valued at $46,089,000 after buying an additional 151,835 shares during the period. Institutional investors and hedge funds own 41.65% of the company's stock.

Zai Lab Stock Up 0.6%

Zai Lab stock traded up $0.21 during mid-day trading on Friday, hitting $32.79. 150,679 shares of the company were exchanged, compared to its average volume of 955,211. The company has a market capitalization of $3.66 billion, a PE ratio of -16.06 and a beta of 1.04. The business has a fifty day moving average of $34.60 and a 200 day moving average of $33.96. Zai Lab has a 1-year low of $20.17 and a 1-year high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The business had revenue of $109.98 million for the quarter, compared to analyst estimates of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. Research analysts expect that Zai Lab will post -2.58 earnings per share for the current year.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.